Solution structure of the equine infectious anemia virus p9 protein: a rationalization of its different ALIX binding requirements compared to the analogous HIV-p6 protein by Sharma, Alok et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Poster presentation
Solution structure of the equine infectious anemia virus p9 protein: 
a rationalization of its different ALIX binding requirements 
compared to the analogous HIV-p6 protein
Alok Sharma1,2, Karsten Bruns1,2, René Röder2,3, Peter Henklein3, 
Jörg Votteler*2, Victor Wray1 and Ulrich Schubert2
Address: 1Department of Structural Biology, Helmholtz Centre for Infection Research, D-38124 Braunschweig, Germany, 2Institute of Virology, 
Friedrich Alexander University of Erlangen-Nürnberg, D-91054 Erlangen, Germany and 3Institute of Biochemistry, Charité-Universitätsmedizin-
Berlin, D-10117 Berlin, Germany
* Corresponding author    
Background
The equine infection anemia virus (EIAV) p9 Gag protein
contains the late (L-) domain required for efficient virus
release of nascent virions from the cell membrane of
infected cells. The genomic position of p9 is analogous to
that of the HIV-1 p6 protein and other similar proteins
from different lentiviruses. Compared to HIV-1 p6, EIAV
p9 has only minimal amino acid sequence homology and
a considerable variation in the predicted secondary struc-
ture. Besides the function of p9 in viral DNA production
and processing of the provirus [1], p9 plays, like p6 of
HIV-1, an essential role in virus release, which is governed
by late assembly domains (L-domains) [2-4].
Results
In the present study the p9 protein and N- and C-terminal
fragments (residues 1-21 and 22-51, respectively) were
chemically synthesized and used for structural analyses.
CD and 1H NMR spectroscopy provide the first molecular
insight into the secondary structure and folding of this 51-
amino acid protein under different solution conditions.
Qualitative 1H chemical shift and NOE data indicate that
in a pure aqueous environment p9 favors an unstructured
state. In its most structured state under hydrophobic con-
ditions, p9 adopts a stable helical structure within the C-
terminus. Quantitative NOE data further revealed that this
α-helix extends from Ser-27 to Ser-48, while the N-termi-
nal residues remain unstructured. The structural elements
identified for p9 differ substantially from that of the func-
tional homologous HIV-1 p6 protein.
Conclusion
These structural differences are discussed in the context of
the different types of L-domains regulating distinct cellu-
lar pathways in virus budding. EIAV p9 mediates virus
release by recruiting the ALG2-interacting protein X
(ALIX) via the YPDL-motif to the site of virus budding, the
counterpart of the YPXnL-motif found in p6 [4,5]. How-
ever, p6 contains an additional PTAP L-domain that pro-
motes HIV-1 release by binding to the tumor
susceptibility gene 101 (Tsg101) [2]. The notion that
structures found in p9 differ form that of p6 further sup-
port the idea that different mechanisms regulate binding
of ALIX to primary versus secondary L-domains types.
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